Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficiency and safety between paclitaxel combined
with epirubicin and vinorelbine combined with epirubicin when used in neoadjuvant
chemotherapy for locally advanced (IIb-IIIc) HER2-negative breast cancer with TEKT4
variations.